Different histological sequelae of immune‐mediated graft dysfunction after interferon treatment in transplanted dual grafts from living donors

Mizuki Ninomiya, Shinichi Aishima, Tomoharu Yoshizumi, Toru Ikegami, Huanlin Wang, Norifumi Harimoto, Shinji Ito, Hideaki Uchiyama, Yuji Soejima, Hirofumi Kawanaka, Ken Shirabe, Yoshihiko Maehara – 11 September 2014

A score model for the continuous grading of early allograft dysfunction severity

Eugenia Pareja, Miriam Cortes, David Hervás, José Mir, Andrés Valdivieso, José V. Castell, Agustín Lahoz – 10 September 2014 – Early allograft dysfunction (EAD) dramatically influences graft and patient outcomes. A lack of consensus on an EAD definition hinders comparisons of liver transplant outcomes and management of recipients among and within centers. We sought to develop a model for the quantitative assessment of early allograft function [Model for Early Allograft Function Scoring (MEAF)] after transplantation.

Perioperative changes in nutritional parameters and impact of graft size in patients undergoing adult living donor liver transplantation

Ahmed Hammad, Toshimi Kaido, Kohei Ogawa, Yasuhiro Fujimoto, Koji Tomiyama, Akira Mori, Tadahiro Uemura, Shinji Uemoto – 10 September 2014 – Derangements of various serum biochemical nutritional/metabolic parameters are common in patients with end‐stage liver disease who undergo liver transplantation (LT). The aim of this study was to explain the benefit of LT with respect to parameter changes and to examine the impact of the graft‐to‐recipient weight ratio (GRWR) on such changes.

Pretransplant lymphopenia is a novel prognostic factor in cytomegalovirus and noncytomegalovirus invasive infections after liver transplantation

Natalie E. Nierenberg, Debra D. Poutsiaka, Jennifer K. Chow, Jeffrey Cooper, Lori Lyn Price, Richard B. Freeman, Richard Rohrer, David R. Snydman – 10 September 2014 – Infection after liver transplantation (LT) remains a leading cause of morbidity and mortality. The risk of infection after LT is highest in those who are most immunosuppressed, but to date, no standard blood marker of one's degree of immunosuppression or risk index has been established.

Effect of sofosbuvir and ribavirin treatment on peripheral and hepatic lipid metabolism in chronic hepatitis C virus, genotype 1–infected patients

Eric G. Meissner, Yu‐Jin Lee, Anu Osinusi, Zayani Sims, Jing Qin, Dan Sturdevant, John McHutchison, Mani Subramanian, Maureen Sampson, Susanna Naggie, Keyur Patel, Alan T. Remaley, Henry Masur, Shyam Kottilil – 9 September 2014 – Hepatitis C virus (HCV) modulates intrahepatic cholesterol biosynthetic pathways to promote viral replication. Chronic HCV infection is associated with altered metabolism, including dyslipidemia and insulin resistance (IR), which contributes to disease progression and influences response to therapy.

Subscribe to